Trial Profile
Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Therapeutic Use
- Acronyms SNIFF-Quick
- 29 Aug 2019 Status changed from recruiting to completed.
- 21 Sep 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 21 Sep 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.